MOUNTAIN VIEW, Calif., Feb. 26 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software and strategic services for optimizing clinical drug development, today announced that it has named Fredrik Jonsson, Ph.D., as senior associate scientist in the Company's Strategic Consulting Services group. Dr. Jonsson will be based in Europe and will draw from his extensive pharmacokinetics experience to advise clients in applying Pharsight's modeling and simulation methodology within their organizations to help optimize decision-making in the drug development process.
Prior to joining Pharsight, Dr. Jonsson was acting associate professor in the Division of Pharmacokinetics and Drug Therapy at Uppsala University in Sweden. He was also visiting scientist at the Karolinska Institute of Environmental Medicine and served an as independent consultant to the pharmaceutical industry.
"Fredrik brings to the Strategic Consulting Group a wealth of expertise in the area of pharmacokinetic and pharmacodynamic modeling and Bayesian methods," said Shawn O'Connor, Pharsight President, CEO and chairman. "Fredrik's deep technical skill set, applied research interests and industry experience will further strengthen our ability to better serve our global consulting clientele. His appointment is another key step as we continue to grow our world-class consulting team at Pharsight."
"I joined Pharsight because their integrated approach to modeling and simulation is leading-edge and will allow me to continue to develop my skill- set, which I believe will be additive to the unit's capabilities," said Dr. Jonsson. "I am looking forward to working with Pharsight's scientific consulting team to further leverage the potential for Pharsight's unique methodology to help pharmaceutical and biotechnology companies optimize their approaches to drug development."
Dr. Jonsson holds a Ph.D. in pharmacokinetics from Uppsala University's division of Pharmacokinetics and Drug Therapy in Sweden. He held a postdoctoral research fellowship at Uppsala University, funded in part by Roche, AstraZeneca and Pfizer. To date, Dr. Jonsson has authored or co- authored more than 20 original research articles, manuscripts and scientific communications in the field of pharmacostatistical modeling. In the industry, Dr. Jonsson has undertaken extensive work in PK/PD modeling in a number of therapeutic areas, for which he has given several invited lectures and presentations.
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com .
Registered Trademarks and Trademarks
Pharsight(R) is a registered trademark of Pharsight Corporation. All other brand and product names are trademarks or registered trademarks of their respective holders.
Pharsight CorporationCONTACT: Investors, Douglas Sherk, or Jennifer Beugelmans, both of EVCGroup, +1-415-896-6820, or Media, Jen Saunders of EVC Group,+1-646-201-5431
Web site: http://www.pharsight.com//
